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KEY POINTS  42 
 43 
Question:  Is the lowering of LDL-cholesterol in the primary prevention of patients with LDL-44 
cholesterol ≥190 mg/dL beneficial? 45 
Findings: in this post-hoc analysis from the WOSCOPS randomised trial of 2560 men with 46 
primary elevations of LDL-cholesterol ≥190 mg/dL but without vascular disease, pravastatin 47 
(vs. placebo) reduced the risk of coronary heart disease (CHD) by 27% and of major adverse 48 
cardiovascular events by 25% over 4.9-years. Randomisation to pravastatin significantly 49 
reduced the risk of CHD death (28%), cardiovascular death (25%) and all-cause mortality 50 
(18%) over a total of 20-years (extended observational long-term follow-up) among those 51 
with LDL-cholesterol ≥190 mg/dL. 52 
Meaning: we provide for the first time evidence from a randomised trial demonstrating the 53 
benefit of LDL-cholesterol lowering for the primary prevention of individuals with primary 54 
elevations of LDL-cholesterol ≥190 mg/dL. 55 
 56 
 57 
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 61 
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ABSTRACT 63 
 64 
Background: Patients with primary elevations of LDL-C ≥190 mg/dL are at a higher risk of 65 
atherosclerotic cardiovascular disease as a result of long-term exposure to markedly 66 
elevated LDL-C levels. Therefore, initiation of statin therapy is recommended for these 67 
individuals. However, there is a lack of randomised trial evidence supporting these 68 
recommendations in primary prevention. In the present analysis we provide hitherto 69 
unpublished data on the cardiovascular effects of LDL-C lowering among a primary 70 
prevention population with LDL-C ≥190 mg/dL. 71 
Methods: we aimed to assess the benefits of LDL-C lowering on cardiovascular outcomes 72 
among individuals with primary elevations of LDL-C ≥190 mg/dL without pre-exiting vascular 73 
disease at baseline. We carried out post-hoc analyses from the West Of Scotland Coronary 74 
Prevention Study (WOSCOPS) randomised, placebo-controlled trial, and observational post-75 
trial long-term follow-up, after excluding individuals with evidence of vascular disease at 76 
baseline. WOSCOPS enrolled 6595 men aged 45-64 years, who were randomised to 77 
pravastatin 40 mg/d or placebo. In the present analyses, 5529 participants without evidence 78 
of vascular disease were included, stratified by LDL-C levels into those with LDL-C <190 79 
mg/dL (n=2969; mean LDL-C 178±6 mg/dL) and those with LDL-C ≥190 mg/dL (n=2560; 80 
mean LDL-C 206±12 mg/dL).  81 
The effect of pravastatin versus placebo on coronary heart disease (CHD) and major adverse 82 
cardiovascular events (MACE) were assessed over the 4.9-year randomised-controlled trial 83 
phase and on mortality outcomes over a total of 20-years of follow-up. 84 
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Results: among 5529 individuals without vascular disease, pravastatin reduced the risk of 85 
CHD by 27% (p=0.002) and MACE by 25% (p=0.004) consistently among those with and 86 
without LDL-C ≥190 mg/dL (p-interaction >0.9). Among individuals with LDL-C ≥190 mg/dL, 87 
pravastatin reduced the risk of CHD by 27% (p=0.033) and MACE by 25% (p=0.037) during 88 
the initial trial phase and the risk of CHD death, cardiovascular death and all-cause mortality 89 
by 28% (p=0.020), 25% (p=0.009) and 18% (p=0.004), respectively, over a total of 20-years of 90 
follow-up. 91 
Conclusions: the present analyses provide robust novel evidence for the short and long-92 
term benefits of lowering LDL-C for the primary prevention of cardiovascular disease among 93 
individuals with primary elevations of LDL-C ≥190 mg/dL. 94 
 95 
[* Note: Trial Registration: the original WOSCOSP trial was carried out between 1988 and 96 
1995 and so it preceded the formal trial registration era. Nevertheless, the protocol and 97 
statistical analysis plan related to the original WOSCOPS trial was pertinently published in an 98 
international peer-reviewed journal and can be consulted as follows: J Clin Epidemiol 99 
1992;45(8):849-60. The results we are reporting in the present manuscript are post hoc 100 
analyses not envisaged in the original protocol; therefore, we provide in the present 101 
manuscript a detailed description of the post hoc analyses design, methods and statistical 102 
analyses carried out.] 103 
 104 
Keywords: lipids and lipoproteins; statin therapy; primary prevention; cardiovascular 105 
disease prevention 106 
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CLINICAL PERSPECTIVE 107 
1) What is new?  108 
 The present analysis from the WOSCOPS trial reports for the first time new 109 
information on over 2500 men with LDL-cholesterol ≥190 mg/dL without pre-existing 110 
vascular disease (a group lacking randomised trial evidence for statin therapy) and 111 
their subsequent risk of cardiovascular events. 112 
 Individuals with a LDL-Cholesterol ≥190 mg/dL have a 2-fold higher observed risk of 113 
major cardiovascular events than would be predicted from a risk calculator.   114 
 We provide compelling novel evidence from a randomised trial supporting the 115 
benefit of LDL-cholesterol lowering on cardiovascular events among a primary 116 
prevention population with LDL-Cholesterol ≥190 mg/dL.  117 
2) What are the clinical implications?  118 
 The present analysis provides novel supporting evidence from a randomised trial to 119 
reinforce current recommendations of initiation of lipid-lowering therapy in the 120 
primary prevention of individuals with primary elevations of LDL-C ≥190 mg/dL 121 
without the need for risk estimation. 122 
 Although these analyses are post-hoc, this approach is the only one that allows us to 123 
address this question currently, since (i) nowadays it would be unethical to perform 124 
a placebo-controlled trial in the population with LDL-C ≥190 mg/dL, and (ii) there is 125 
no other randomised trial in primary prevention with statins including such a 126 
significant proportion of patients with an LDL-C ≥190 mg/dL. 127 
  128 
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MAIN TEXT 129 
 130 
Introduction 131 
Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL 132 
(to convert values for cholesterol to mmol/L, multiply by 0.02586) are at a higher risk of 133 
atherosclerotic cardiovascular disease (ASCVD) as a result of a long-term exposure to 134 
markedly elevated LDL-C levels, even in the absence of pre-existing ASCVD (i.e. primary 135 
prevention).1,2 This has been recently further supported by observations from the 136 
Cardiovascular Lifetime Risk Pooling Project where these individuals, who were even 137 
referred to as “FH phenotype” (eTable 1 in the Supplement), were observed to have an 138 
accelerated risk of coronary heart disease (CHD) and ASCVD compared to individuals with 139 
“average” levels of LDL-C.3 As such, initiation of statin therapy (and more recently also of 140 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to further reduce LDL-C 141 
levels) is recommended for individuals with primary elevations of LDL-C ≥190 mg/dL without 142 
the need for risk assessment.1,2,4 However, there is a lack of published randomised trial 143 
evidence supporting these recommendations in primary prevention with available evidence 144 
extrapolated from the Cholesterol Treatment Trialist (CTT) meta-analyses (where lower LDL-145 
C cut-off points were used and patients with established vascular disease were included in 146 
the high LDL-C category).5,6 147 
Currently it would be unethical to perform a placebo-controlled trial of LDL-C lowering 148 
therapy among individuals with LDL-C ≥190 mg/dL. Nonetheless, we can address this 149 
question using data from the West Of Scotland Coronary Prevention Study (WOSCOPS), 150 
which aimed to assess the benefits of statin therapy among men with 151 
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hypercholesterolaemia and enrolled a significant proportion of patients with LDL-C ≥190 152 
mg/dL (mean LDL-C 192 mg/dL).7,8 Although WOSCOPS excluded individuals with apparent 153 
myocardial infarction (MI), a proportion of participants still had evidence of other vascular 154 
diseases at baseline.  155 
In the present analysis, we provide hitherto unpublished data on the cardiovascular effects 156 
of LDL-C lowering among a population with primary elevation of LDL-C ≥190 mg/dL after 157 
restricting analyses to participants without evidence of vascular disease at baseline. 158 
Furthermore, clinical guidelines have differed on whether to recommend percentage 159 
reductions in LDL-C or specific LDL-C levels among such patients1,9,10. To provide practical 160 
insights into desirable reductions in LDL-C among these individuals, we also conducted an 161 
observational analysis which assessed the relationship between reductions in LDL-C (in 162 
relative or absolute terms) and on-treatment LDL-C levels with subsequent clinical events.  163 
Methods 164 
Randomised trial 165 
Details of the design of WOSCOPS have been described in detail elsewhere.7,8 Briefly, 166 
WOSCOPS enrolled 6595 men aged 45-64 years (mean age 55 years) without evidence of 167 
prior MI and with a LDL-C ≥155 mg/dL not receiving lipid lowering therapy (mean LDL-C 192 168 
mg/dL). Patients likely to have an elevated LDL-C due to secondary causes or with LDL-C 169 
>232 mg/dL on two fasting lipid measurements during the screening phase were excluded 170 
(supplementary eMethods, eFigure 1). Subjects were then randomised (double-blind) to 171 
pravastatin 40 mg once daily or placebo. Mean follow-up was 4.9 years (range 3.1-6.1).  172 
To assess a purely primary prevention population the present analyses adopted more 173 
rigorous criteria than those used in the main WOSCOPS trial and additionally excluded those 174 
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individuals with any evidence of vascular disease at baseline (n=1066) namely, evidence of 175 
angina, intermittent claudication, stroke, transient ischemic attack, and minor ECG 176 
abnormalities (classified by Minnesota code).7,8,11 Patients were then stratified by LDL-C 177 
levels at baseline into those with LDL-C <190 mg/dL and those with LDL-C ≥190 mg/dL, 178 
eFigure 1, eTable 1. The following principal endpoints were considered for the present 179 
analysis in order to maximise power (given the smaller sample size resulting from the 180 
stricter exclusion criteria and further restricting analysis to approximately half of the 181 
remaining individuals, i.e. participants with LDL-C ≥190 mg/dL): (i) the composite of definite 182 
or suspected non-fatal MI plus definite or suspected CHD death, hereinafter referred to as 183 
CHD (same co-principal endpoint as the original WOSCOPS trial); (ii) the composite of 184 
cardiovascular death, non-fatal MI (definite or suspected) and non-fatal stroke (major 185 
adverse cardiovascular events [MACE]). Endpoint definitions including definite and 186 
suspected coronary events are shown in the supplementary methods. Other outcomes 187 
explored include the principal endpoints but restricted to definite-only coronary events, 188 
MACE including coronary revascularisation, mortality endpoints (CHD death, cardiovascular 189 
death and all-cause mortality), coronary revascularization, and cerebrovascular events 190 
(fatal/non-fatal stroke and transient ischemic attack).  191 
Extended observational long-term follow-up 192 
After completion of the randomised trial phase an extended observational follow-up of the 193 
WOSCOPS cohort is now ongoing, through linkage to national mortality and electronic 194 
hospital discharge records held by the National Health Service for Scotland.12,13 Further 195 
details are available in the supplementary methods, but briefly at 5 years after the initial 196 
trial finished approximately one third of individuals originally allocated to pravastatin or 197 
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placebo were on statins. In the present analysis we compared long-term mortality outcomes 198 
(including deaths from CHD, cardiovascular causes, and any-cause) between those originally 199 
randomised to pravastatin compared with placebo among individuals without evidence of 200 
vascular disease at baseline stratified by hypercholesterolaemia status.  201 
Ethics 202 
The ethics committees from the University of Glasgow and participating health boards in 203 
Scotland approved the original WOSCOPS trial. The corresponding committees from the 204 
Glasgow Royal Infirmary and Privacy Advisory Committee of the National Health Service for 205 
Scotland approved the extended follow-up study. The participants in each phase of 206 
WOSCOPS provided informed consent to partake in the trial and review of their medical 207 
records. 208 
Statistical analysis 209 
Effect of statin therapy on outcomes 210 
The effect of therapy (pravastatin vs. placebo) among those with and without LDL-C ≥190 211 
mg/dL was calculated for both the initial trial period and the extended follow-up. Estimates 212 
of hazard ratios and 95% confidence intervals with corresponding p-values were obtained by 213 
means of Cox proportional-hazards model with randomised therapy as the only covariate. A 214 
test for interaction was performed to assess whether the effect of therapy was consistent 215 
across the LDL-C strata pre-specified for this analysis. The p-value obtained from the 216 
treatment by LDL-C subgroup interaction term was reported. Time-to-event curves were 217 
estimated using the Kaplan-Meier method based on the original treatment arm and LDL-C 218 
strata. Tests were 2-sided and statistical significance defined as p<0.05. 219 
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Changes in LDL-C and outcomes 220 
To elucidate the extent to which the magnitude of LDL-C reduction from pravastatin therapy 221 
influenced outcomes among those with LDL-C ≥190 mg/dL, observational analyses were 222 
performed. Therefore, we assessed changes in LDL-C levels and pravastatin effect during the 223 
randomised trial restricted to those subjects with LDL-C ≥190 mg/dL at baseline. The 224 
placebo group was taken as the reference category for the models. The relationship 225 
between absolute LDL-C fall (mean baseline level minus mean on-treatment value) or 226 
percentage LDL-C reduction and risk of events were assessed using multivariable Cox 227 
regression models (Wald test) for the different groups (placebo and pravastatin subgroups), 228 
accounting for the following covariates: age, smoking, blood pressure, history of 229 
hypertension, diabetes mellitus, and body mass index, as previously published.5,14 LDL-C 230 
reductions were modelled as categorical variables based on previous WOSCOPS and CTT 231 
publications.5,6,14 For the assessment of the relative fall in LDL-C, above and below 30% was 232 
used (consistent with the perceived average potency of pravastatin 40 mg/day: moderate-233 
intensity statin therapy).1 234 
On-treatment LDL-C and outcomes 235 
The relationship between on-treatment LDL-C levels achieved with therapy on the risk of 236 
events was studied following similar analyses to those described above. Consistent with 237 
previous WOSCOPS analyses,14 “on-treatment lipid levels” were defined as the mean of all 238 
lipid values measured after randomisation until the patient had an event or reached the end 239 
of the trial. On-treatment LDL-C analyses excluded individuals with events in the first 6 240 
months of the trial as first on-treatment lipid measurements were at 6 months after 241 
randomisation.  242 
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Participants with a predicted 10-year ASCVD risk below 7.5% and no diabetes 243 
Finally, we performed additional analyses among participants without an indication of statin 244 
therapy based on global cardiovascular risk estimation and who were free from diabetes in 245 
whom LDL-C was ≥190 mg/dL (and for comparison below 190 mg/dL), to specifically assess 246 
the impact of LDL-C related-cardiovascular risk. To assess global cardiovascular risk we 247 
applied the Pooled Cohort Risk Equations15 to the WOSCOPS cohort who were free from 248 
ASCVD and diabetes, restricted to those with a predicted 10-year ASCVD risk below 7.5%. To 249 
maximise power we focused on MACE during the 5-year on-trial period and 20-year 250 
extended follow-up.  251 
The statistical analyses were performed using SAS v9.2 (SAS Institute Inc., USA). 252 
Results 253 
A total of 5529 patients without prior evidence of vascular disease were included in the 254 
present analyses; of these, 2560 individuals had LDL-C ≥190 mg/dL (placebo n=1274; 255 
pravastatin n=1286). The baseline characteristics, stratified by presence or absence of LDL-C 256 
≥190 mg/dL, comparing pravastatin to placebo treatment groups are shown in table 1. 257 
Overall, patients had a mean age of 55 years and there were no significant differences 258 
between placebo and pravastatin treated groups in any of the characteristics. 259 
Lipid levels 260 
LDL-C levels at baseline, 1 year and end of trial, as well as percentage changes from baseline 261 
to year 1 and to end of trial, are shown in table 1. Mean (±SD) LDL-C at baseline was 206±12 262 
mg/dL among patients with LDL-C ≥190 mg/dL, and 178±6 mg/dL among those with LDL-C 263 
<190 mg/dL. LDL-C levels at year 1 and end of trial were significantly lower among 264 
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pravastatin treated subjects compared to placebo across cohorts (p<0.001). The percentage 265 
reduction in LDL-C from baseline with pravastatin (accounting for the effect of placebo) 266 
among those with and without LDL-C ≥190 mg/dL was of a similar magnitude 267 
(approximately 23% at year 1 and 19.5-20% at end of trial), eFigure 2. The effects on other 268 
lipids are shown in eTable 2. 269 
Initial trial phase 270 
The effect of pravastatin versus placebo on cardiovascular outcomes over 4.9 years 271 
stratified by LDL-C <190 or ≥190 mg/dL is shown in figure 1, table 2 and eTable 3. Overall, 272 
both CHD and MACE were reduced in the 5529 patients without vascular disease. Analyses 273 
stratified by LDL-C status showed no evidence of heterogeneity between cohorts for the 274 
principal endpoints or for the additional outcomes explored (interaction p-value all >0.2) 275 
(interaction results did not materially change when using LDL-C as a continuous measure 276 
rather than categorical, eTable 4). The corresponding Kaplan-Meier curves are shown in 277 
figures 2-3 and eFigures 3-5. Among individuals with LDL-C ≥190 mg/dL, pravastatin 278 
significantly reduced the risk of CHD by 27% (p=0.033) with a 25% risk reduction in MACE 279 
(p=0.037). 280 
Long-term follow-up 281 
The effect of initial randomisation to pravastatin or placebo on mortality endpoints during a 282 
total of 20-years of follow-up (from randomisation to end of extended follow-up) is shown 283 
in figure 4, and eFigures 6-8. Overall, amongst all subjects initially allocated to pravastatin 284 
CHD death, cardiovascular death and all-cause mortality were significantly reduced by 22%, 285 
17% and 12% respectively (table 2). Long-term risk of CHD death, cardiovascular death and 286 
all-cause mortality were significantly reduced by 28%, 25% and 18%, respectively, among 287 
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those with LDL-C ≥190 mg/dL originally randomised to pravastatin. The absolute reduction 288 
in the risk (ARR) of death at 20 years from CHD, cardiovascular causes and from any-cause 289 
was at least two-fold greater among patients with LDL-C ≥190 mg/dL (ARR 2.34%, 3.25% and 290 
5.39%, respectively) compared with those with LDL-C <190 mg/dL (Table 2). Analysis 291 
considering specifically the post-trial period only (15-year end of randomised trial to end of 292 
extended follow-up period) did not materially change the results (eTable 5). 293 
Change in LDL-C and outcomes 294 
Among individuals with LDL-C ≥190 mg/dL, reduction in LDL-C of greater than 30% or 39 295 
mg/dL (1 mmol/L) were associated with a lower risk of CHD and MACE compared to placebo 296 
(figure 5, eTables 6-7). In contrast, those individuals allocated to pravastatin whose LDL-C 297 
reduction was less than 30% or 39 mg/dL were not significantly different from placebo. 298 
Consistent with earlier publications from WOSCOPS, we did not observe a continuous 299 
relationship between lower achieved LDL-C and outcomes (figure 5, eTables 6-8).  300 
Participants with a predicted 10-year ASCVD risk below 7.5% and no diabetes 301 
Using the Pooled Cohort Risk Equations15 participants were stratified into those free from 302 
diabetes and with a 10-year predicted risk of MACE at baseline of <7.5% but with a LDL-C ≥ 303 
190 mg/dl (n=1714), representing 67% of the initial primary prevention cohort with LDL-C ≥ 304 
190 mg/dl (table 3). During the 5-year trial period MACE was significantly reduced to 4.8% 305 
among those allocated to pravastatin in contrast to a rate of 7.5% among placebo, 306 
representing a 38% reduction in risk (HR 0.62, 95%CI 0.42, 0.92), p=0.018). During the 20-307 
year extended follow up the corresponding rates were 18.76% vs 24.18%, representing a 308 
risk reduction of 27% (HR 0.73, 95%CI 0.60, 0.90, p=0.003). There was no evidence of 309 
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heterogeneity among those with LDL-C less than 190 mg/dL and a predicted 10-year risk less 310 
than 7.5% treated with pravastatin (table 3 and eTable 9). 311 
Discussion 312 
Observational data support the assertion that having a LDL-C ≥190 mg/dL is associated with 313 
increased cardiovascular risk, even in the absence of other risk factors.3 However, current 314 
guidelines recognise the paucity of evidence for primary prevention among these individuals 315 
and, specifically, the lack of evidence from randomised trials which include only patients 316 
with LDL-C ≥190 mg/dL.1 Instead, indirect evidence derived from the extrapolation of other 317 
data is used to support this viewpoint.1 Indeed, the largest evidence base is derived from the 318 
CTT meta-analyses, where a significant reduction in major coronary events and major 319 
vascular events per 39 mg/dL reduction in LDL-C with statins were observed across different 320 
categories of baseline LDL-C, including those with LDL-C ≥135 mg/dL5 or with LDL-C >174 321 
mg/dL6; but these groups included patients with established vascular disease. Thus, while 322 
the primary prevention of adults with primary LDL-C ≥190 mg/dL is identified as one of the 323 
groups where the benefit of statin therapy exceeds the risk of adverse events the data 324 
currently available from randomised clinical trials are still limited.1,2 325 
The present analyses from the WOSCOPS study provide for the first time, evidence from a 326 
randomised trial supporting the benefit of LDL-C reduction in the primary prevention of 327 
ASCVD in those with LDL-C ≥190 mg/dL. Specifically, we provide three lines of evidence for 328 
the benefit of LDL-C lowering with statins in these patients: (i) randomised trial evidence 329 
that LDL-C reduction by approximately one quarter with statins reduces the risk of CHD by 330 
27% and of MACE by 25%; (ii) extended follow-up evidence that the early benefits extend to 331 
reductions in CHD death by 28%, cardiovascular death by 25%, and all-cause mortality by 332 
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18% over 20 years; the greater absolute benefit and smaller numbers needed-to-treat in 333 
patients with LDL-C ≥190 mg/dL likely reflect the higher lifetime cardiovascular risk due to 334 
the cumulative atherosclerotic burden compared with those with LDL-C <190 mg/dL; (iii) 335 
observational data showing that reductions above 30% or 39 mg/dL are associated with 336 
lower risk of CHD and MACE compared to placebo. Another consideration of  our results is 337 
that LDL-C does not appear to be an effect modifier of outcomes at either 5 years or at 20 338 
years of follow-up (all interaction p-values >0.18); in addition, there is not much difference 339 
in event rates based on LDL-C cut-off of 190 mg/dL during the initial 5 year trial period. 340 
While these data provide support for statin therapy for primary prevention in subject with 341 
LDL-C ≥190 mg/dL, the data also provide support for the use of statin therapy for those with 342 
LDL-C <190 mg/dL (lower limit for inclusion being 155 mg/dL).  343 
To assess the importance of LDL-C to cardiovascular risk we conducted an analysis among 344 
the primary prevention cohort in WOSCOPS who were free from diabetes at baseline and 345 
who on the basis of the current Pooled Cohort Risk Equations would be considered at low 346 
risk (i.e. 10-year predicted risk below 7.5%) and otherwise would be ineligible for statin 347 
therapy (approximately two thirds). Among placebo-treated patients with LDL-C ≥190 mg/dL 348 
the observed risk of MACE at 5 years was already 7.5%, i.e. double what would have been 349 
predicted using a risk calculator. In comparison, among those with a LDL-C between 155 and 350 
190 mg/dL the 5-year risk of MACE was 5.7% in the placebo group. These data reinforce the 351 
notion that among patients with a LDL-C ≥190 mg/dL the observed risk is much greater than 352 
would be predicted through a risk calculator, and thus global risk estimation is not 353 
necessary. During the 5-year randomised trial period patients with a LDL-C ≥190 mg/dL but 354 
with a 10-year predicted risk below 7.5% derived a statistically significant 2.7% ARR in MACE 355 
with pravastatin (relative risk reduction 38%). 356 
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We studied a primary prevention population with a LDL-C ≥190 mg/dL, also defined by some 357 
guidelines as primary severe hypercholesterolaemia1. Some have also referred to patients 358 
with LDL-C ≥190 mg/dL as FH phenotype3,4 (eTable 1). However, FH does not have a “gold 359 
standard” definition and its prevalence may ultimately depend on the LDL-C threshold and 360 
the presence of a pathogenic gene variant.16,4 Notwithstanding this, individuals with LDL-C 361 
≥190 mg/dL are more likely to have FH by clinical and/or genetic criteria (eTable 1).9,17-19 362 
However, according to a recent study, only a small proportion of people with severe 363 
hypercholesterolaemia in the community have an identifiable FH mutation.16 In the present 364 
study we lacked genetic data and indeed relevant clinical information to help define FH in 365 
the WOSCOPS population according to accepted diagnostic criteria;9 however, the number 366 
of individuals who fulfil the strict clinical or genetic criteria for FH in the present analyses is 367 
likely to have been small, as WOSCOPS excluded patients with LDL-C >232 mg/dL or with 368 
prior MI.7 Hence, a number of patients with more severe manifestations of FH (in terms of 369 
higher LDL-C levels or coronary disease at an earlier age) might have been excluded. 370 
Nevertheless, our results are applicable to the broader FH population, based on (i) that 371 
there was no heterogeneity in treatment effect between patients with and without LDL-C 372 
≥190 mg/dL, (ii) our observation that individuals with primary elevation of LDL-C ≥190 373 
mg/dL and likely greater lifetime burden from elevated LDL-C derive significant risk 374 
reductions from LDL-C lowering, (iii) a number of observational studies that suggest FH 375 
patients benefit of statins.20-23 376 
The ACC/AHA cholesterol guidelines recommend high-intensity statin therapy for individuals 377 
with LDL-C ≥190 mg/dL1 and whilst the present analyses provide direct evidence for the 378 
benefits for approximately a 23% reduction in LDL-C (i.e. a low-intensity statin regimen), 379 
there are no trials presently capable of providing similar evidence for the benefit of even 380 
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greater percentage reductions or higher intensity statin therapy in this population. Whilst 381 
the current paradigm is that lower on-treatment LDL-C levels and/or greater reductions in 382 
LDL-C are associated with a lower risk of ASCVD,24-26 we did not find evidence for a 383 
continuous relationship between on-treatment LDL-C and better outcomes, which is 384 
consistent with earlier analyses from the overall WOSCOPS cohort.14 To what degree this 385 
reflects studies of pravastatin and its relevance to more contemporary statin use is 386 
uncertain. Since the inclusion criteria was an LDL-C of 155-232 mg/dL and the average LDL-C 387 
reduction at 1 year was approximately 23%, we did not have the data to validate or refute 388 
the current recommendation for a LDL-C target of 100 mg/dL in some guidelines.9,10 389 
When LDL-C reductions in the pravastatin group were analysed as a binary trait, the present 390 
analyses suggested that those individuals who derived >30% reduction or >39 mg/dL 391 
absolute lowering in LDL-C, appeared to derive significant benefit compared to placebo. It 392 
should however be recognised that there was considerable overlap in the observed benefits 393 
between this group and those achieving lesser reductions on pravastatin. We also need to 394 
acknowledge that a fair number of people in the lower effect group never took the 395 
treatment or withdrew from treatment. We know that 9% of the original WOSCOPS cohort 396 
never took the treatment and about 30% were off treatment by 5 years (no significant 397 
difference in the withdrawal rates between pravastatin and placebo arms).8 Many of these 398 
people attended the annual visits and got their lipids assessed because they saw the study 399 
doctor and had ECGs recorded. Hence, we cannot say that any trends to differences seen 400 
are differences in statin response. 401 
The high baseline LDL-C and the limited potency of pravastatin 40 mg/day limit the extent of 402 
the analyses which can be performed in WOSCOPS. Direct evidence for the benefit of even 403 
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greater reductions in LDL-C among patients with LDL-C ≥190 mg/dL in primary prevention 404 
may be inferred indirectly from the recently reported “Studies of PCSK9 Inhibition and the 405 
Reduction of Vascular Events” (SPIRE)-2 trial,27-29 evaluating the efficacy of PCSK9 inhibition 406 
with bococizumab in reducing the risk of major cardiovascular events in subjects with LDL-C 407 
≥100 mg/dL despite maximally tolerated statin therapy. With a mean baseline LDL-C level of 408 
134 mg/dL and assuming a 50% reduction in LDL-C from intensive-statin therapy it suggests 409 
that many participants in the SPIRE-2 trial likely started with untreated LDL-C levels ≥190 410 
mg/dL. Therapy with bococizumab led to a reduction in LDL-C levels of around 55% and 40% 411 
at 14 and 52 weeks, respectively.29 Although the trial was prematurely stopped due to the 412 
development of high rates of antidrug antibodies and attenuation of the cholesterol 413 
lowering effect over time, a significant 21% risk reduction of cardiovascular events was 414 
observed in those treated with bococizumab (compared to placebo) after a median follow-415 
up of 12 months, with no significant differences in analyses stratified by the presence or 416 
absence of clinical evidence of cardiovascular disease.29 Of note, the USA National Lipid 417 
Association has recently recommended that therapy with PCSK9 inhibitors may be 418 
considered to further reduce LDL-C in patients with LDL-C ≥190 mg/dL.4   419 
A major strength of the present analysis is that it explores a group of higher risk individuals 420 
(LDL-C ≥190 mg/dL) specifically highlighted in guidelines, but one in which clinical trial 421 
evidence is lacking.1 Thus, the present results from a randomised trial provide novel 422 
information and evidence to support guideline recommendations. Additionally, since high 423 
lipid levels like those included in WOSCOPS (LDL-C ≥155 mg/dL) may be present in a 424 
significant proportion of the population, the results of the present study may impact on the 425 
care of a significant number of patients; for instance, recent surveys from USA have 426 
estimated a prevalence of 16%-33% for LDL-C ≥155-160 mg/dL and of 5.6%-10.4% for LDL-C 427 
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≥190 mg/dL (depending on the characteristics of the population scrutinised) in the adult 428 
population.30,31 That said, some aspects of the present analyses warrant further discussion. 429 
This is an analysis of a subgroup of the overall WOSCOPS cohort which was not pre-specified 430 
and, whilst the findings are consistent with the original trial publications,8,12-14 the present 431 
findings remain post-hoc. The lack of statistically significant reductions in additional 432 
endpoints in the group with LDL-C ≥190 mg/dL (figure 1) may reflect a limited power 433 
resulting from restricting the original sample size. In addition, it should be noted that the 434 
LDL-C levels in those with LDL-C <190 mg/dL were still high (mean LDL-C at baseline 178 435 
mg/dL overall; at year 1: 177 and 135 mg/dL in placebo and pravastatin arms, respectively) 436 
and not markedly different than in those with LDL-C ≥190 mg/dL (mean LDL-C at baseline 437 
206 mg/dL overall; at year 1: 199 and 157 mg/dL in placebo and pravastatin arms, 438 
respectively); as such, the difference in absolute risk reduction between these groups may 439 
not have been as wide as could be observed in current populations where mean LDL-C levels 440 
(in those with LDL-C <190 mg/dL) are significantly lower.  441 
The extended long-term follow-up reports data among individuals enrolled in the original 442 
trial and, although the comparisons provided are for the original randomised groups, it 443 
should be recognised that the data from the additional 15 years of follow-up after the 444 
original trial was completed are observational and might be confounded by the lack of 445 
ongoing information regarding medication use. For instance, those participants with LDL-C 446 
≥190 mg/dL may have been more likely kept on treatment than those with lower LDL-C 447 
levels after the completion of the trial. Nevertheless, it provides valuable information on 448 
what a period of treatment may confer in terms of long-term risk reduction benefit (“legacy 449 
effect” or “reset of the atherosclerotic event clock” based on the original trial). 450 
Nevertheless, without excluding the possibility of confounding factors it is not possible to 451 
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fully characterize the long-term follow-up estimates as either underestimates or 452 
overestimates since it cannot be assumed that the outcomes are only modulated by statin 453 
use or non-use. Notwithstanding this, we consider the former is more likely due to the fact 454 
that (i) many actively treated patients during the trial phase may have no longer received 455 
statin therapy and (ii) the expected increased cross-over in the original placebo arm to statin 456 
therapy during follow-up; as such, the results of the extended follow-up may likely 457 
underestimate the benefits of longer-term therapy due to reduced differential statin use 458 
over time, and so likely the benefit for those ≥190 mg/dL may be larger than that implied by 459 
the trial (especially if one were to use a statin regimen of greater potency to that used in 460 
WOSCOPS). On the other hand, the high prevalence of smokers in the WOSCOPS population 461 
might mean that a similar study today might not show as strong an effect with a statin 462 
regimen of similar potency.  463 
Regarding the exploratory analyses evaluating LDL-C change on treatment versus outcome 464 
(compared with placebo), it cannot completely rule out the influence of non-compliance to 465 
medication. That said, to be included in the analysis men had to attend to have their blood 466 
sample taken; many non-compliers did not do so (which is why the achieved LDL-C rose 467 
slightly over time). Thus, there is some allowance for non-compliance in the analysis as 468 
performed. Finally, the analyses of reductions in LDL-C on pravastatin and outcomes are 469 
observational in nature and should be interpreted as such as residual confounding cannot 470 
be excluded despite statistical adjustment.  471 
Conclusion 472 
Among men with primary elevations of LDL-C levels ≥190 mg/dL, primary prevention with 473 
pravastatin reduced the risk of cardiovascular events. Thus, the present analyses from a 474 
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randomised clinical trial provides for the first time evidence for the benefits of LDL-C 475 
lowering for the primary prevention of individuals with primary elevations of LDL-C ≥190 476 
mg/dL, which may help reinforce current recommendations for this group of patients.  477 
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FIGURE LEGENDS 682 
 683 
Figure 1. Endpoints during the randomised trial period, overall and stratified by LDL-684 
cholesterol levels at baseline. 685 
Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% 686 
confidence interval (95% CI). (*) Including coronary events (i.e. non-fatal MI and CHD death) 687 
as definite only. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. 688 
MACE: major adverse cardiovascular events, defined as the composite of cardiovascular 689 
death, non-fatal myocardial infarction and non-fatal stroke. TIA: transient ischemic attack. 690 
To convert values for cholesterol to mmol/L, multiply by 0.02586.  691 
 692 
Figure 2. Coronary heart disease risk: Kaplan-Meier curves during the randomised trial 693 
period stratified by LDL-cholesterol levels at baseline and treatment allocation. 694 
5-year follow-up Kaplan-Meier analysis for coronary heart disease (CHD) endpoint, stratified 695 
by LDL-cholesterol at baseline (<190 or ≥190 mg/dL) and treatment allocation at 696 
randomisation (pravastatin or placebo). Number of events in each group were as follows: 697 
placebo, LDL-C <190 mg/dL: n=104; pravastatin, LDL-C <190 mg/dL: n=75; placebo, LDL-C 698 
≥190 mg/dL: n=107; pravastatin, LDL-C ≥190 mg/dL: n=80. CI: confidence interval. HR: 699 
hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. 700 
 701 
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Figure 3. Major adverse cardiovascular events risk: Kaplan-Meier curves during the 702 
randomised trial period stratified by LDL-cholesterol levels at baseline and treatment 703 
allocation. 704 
5-year follow-up Kaplan-Meier analysis for major adverse cardiovascular disease events 705 
(MACE) endpoint, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and 706 
treatment allocation at randomisation (pravastatin or placebo). Number of events in each 707 
group were as follows: placebo, LDL-C <190 mg/dL: n=119; pravastatin, LDL-C <190 mg/dL: 708 
n=90; placebo, LDL-C ≥190 mg/dL: n=121; pravastatin, LDL-C ≥190 mg/dL: n=93. MACE: 709 
major adverse cardiovascular events, defined as the composite of cardiovascular death, 710 
non-fatal myocardial infarction and non-fatal stroke. CI: confidence interval. HR: hazard 711 
ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. 712 
 713 
Figure 4. Long-term mortality endpoints at 20 years of follow-up, overall and stratified by 714 
LDL-cholesterol levels at baseline. 715 
Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% 716 
confidence interval (95% CI). CHD: coronary heart disease. LDL-C: low-density lipoprotein 717 
cholesterol. To convert values for cholesterol to mmol/L, multiply by 0.02586.  718 
   719 
Figure 5. Principal endpoints during the randomised trial period based on different 720 
categories of LDL-C levels with pravastatin in subjects with LDL-cholesterol ≥190 mg/dL at 721 
baseline. 722 
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Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% 723 
confidence interval (95% CI). Note that MACE plus coronary revascularisation endpoint was 724 
used here instead of MACE alone in order to increase the number of events in each stratum 725 
and so the power of the analysis in an otherwise restricted sample to those with LDL-C ≥190 726 
mg/dL allocated to pravastatin further stratified in different groups as shown in the table. 727 
HR are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic 728 
and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as 729 
the mean of all LDL-C values measured after randomisation until the patient had an event or 730 
reached the end of the study. On-treatment LDL-C analyses excluded individuals with events 731 
in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months 732 
after randomisation. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse 733 
cardiovascular events, defined as the composite of cardiovascular death, non-fatal 734 
myocardial infarction and non-fatal stroke. To convert values for cholesterol to mmol/L, 735 
multiply by 0.02586. 736 
 737 
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 739 
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 741 
 742 
 743 
 744 
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TABLE 1. Characteristics of the participants without vascular disease at enrolment stratified by LDL-cholesterol levels at baseline. 1 
 2 
 Participants LDL-C <190 mg/dL Participants With LDL-C ≥190 mg/dL 
 Placebo Pravastatin Placebo Pravastatin 
 n = 1493 n = 1476 n = 1274 n = 1286 
Demographics at baseline     
Age (years) 54.8 ± 5.5 55.0 ± 5.6 54.7 ± 5.5 54.8 ± 5.5 
Body mass index (kg/m2) 25.9 ± 3.1 25.8 ± 3.2 25.8 ± 3.1 25.8 ± 3.0 
Systolic BP (mmHg) 134.8 ± 16.3 134.6 ± 17.0 135.2 ± 17.1 134.5 ± 17.4 
Diastolic BP (mmHg) 83.8 ± 10.2 83.5 ± 10.5 83.8 ± 9.9 83.6 ± 10.4 
History of hypertension, n (%) 194 (13.0) 199 (13.5) 164 (12.9) 188 (14.6) 
History of diabetes, n (%) 13 (0.9) 12 (0.8) 13 (1.0) 21 (1.6) 
Current smoker, n (%) 634 (42.5) 594 (40.2) 563 (44.2) 583 (45.3) 
Lipid levels at baseline     
LDL-Cholesterol (mg/dL) 178.5 ± 6.5 178.2 ± 6.7 206.6 ± 12.8 206.7 ± 12.7 
Total cholesterol (mg/dL) 258.0 ± 15.3 257.7 ± 15.7 286.6 ± 19.1 286.3 ± 18.9 
HDL-Cholesterol (mg/dL) 44.3 ± 9.6 44.7 ± 9.7 44.4 ± 9.6 44.1 ± 8.9 
Non-HDL-Cholesterol (mg/dL) 213.8 ± 16.2 213.0 ± 16.5 242.2 ± 19.5 242.3 ± 19.2 
Triglycerides (mg/dL) 143.9 (108.5, 194.9) 139.5 (106.3, 190.4) 150.6 (115.1, 197.1) 148.4 (115.1, 192.6) 
LDL-Cholesterol levels during the follow-up      
LDL-C Year 1 (mg/dL) 177.8 ± 21.7 135.8 ± 29.2 199.8 ± 26.0 152.7 ± 33.3 
LDL-C End of trial (mg/dL) 179.1 ± 24.3 142.9 ± 32.0 199.6 ± 28.7 158.4 ± 35.4 
Percentage change from baseline to 1 year -0.4 ± 11.9 -23.8 ± 16.2 -3.1 ± 11.8 -26.1 ± 15.5 
Percentage change from baseline to end of trial 0.4 ± 13.4 -19.8 ± 17.7 -3.2 ± 13.1 -23.3 ± 16.7 
 3 
Data shown as absolute and relative (%) number of subjects for categorical variables and as mean ± standard deviation or median (interquartile range) for continuous parameters. BP: blood pressure. HDL: 4 
high-density lipoprotein. LDL-C: low-density lipoprotein cholesterol. To convert values for cholesterol to mmol/L, multiply by 0.02586. To convert values for triglycerides to mmol/L, multiply by 0.01129. 5 
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TABLE 2. Principal and mortality endpoints during the randomised trial period, and long-term mortality endpoints from randomisation to 20 years of 1 
follow-up, stratified by LDL-cholesterol levels at baseline. 2 
 3 
 4 
 5 
 Overall cohort Participants with LDL-C <190 mg/dL Participants With LDL-C ≥190 mg/dL Interaction p-
value between 
LDL-C grouping 
at baseline and 
randomised 
treatment 
 
HR (95% CI), p-value 
Events [n (%)] 
HR (95% CI), p-value 
Events [n (%)] 
HR (95% CI), p-value 
 
Placebo 
(n=1493) 
Pravastatin 
(n=1476) 
Placebo 
(n=1274) 
Pravastatin 
(n=1286) 
5-year randomised trial        
CHD  0.73 (0.59, 0.89), 0.002 104 (6.97%) 75 (5.08%) 0.72 (0.54, 0.97), 0.032 107 (8.40%) 80 (6.22%) 0.73 (0.55, 0.98), 0.033 0.960 
MACE 0.75 (0.62, 0.91), 0.004 119 (7.97%) 90 (6.10%) 0.76 (0.58, 1.00), 0.048 121 (9.50%) 93 (7.23%) 0.75 (0.57, 0.98), 0.037 0.958 
CHD death 0.91 (0.56, 1.48), 0.704 18 (1.21%) 17 (1.15%) 0.95 (0.49, 1.85), 0.887 16 (1.26%) 14 (1.09%) 0.86 (0.42, 1.76), 0.684 0.838 
Cardiovascular death 0.84 (0.54, 1.30), 0.434 24 (1.61%) 20 (1.36%) 0.84 (0.46, 1.52), 0.568 20 (1.57%) 17 (1.32%) 0.84 (0.44, 1.60), 0.590 0.992 
All-cause mortality 0.87 (0.64, 1.17), 0.356 52 (3.48%) 46 (3.12%) 0.89 (0.60, 1.33), 0.576 40 (3.14%) 34 (2.64%) 0.84 (0.53, 1.32), 0.446 0.835 
20-year long-term follow-up        
CHD 0.74 (0.65, 0.84), <0.001 268 (17.95%) 201 (13.62%) 0.73 (0.61, 0.88), <0.001 261 (20.49%) 203 (15.79%) 0.74 (0.61, 0.89), 0.001 0.942 
MACE 0.79 (0.71, 0.88), <0.001 383 (25.65%) 306 (20.73%) 0.77 (0.66, 0.89), <0.001 344 (27.00%) 295 (22.94%) 0.81 (0.69, 0.94), 0.007 0.642 
CHD death 0.78 (0.64, 0.94), 0.011 115 (7.70%) 96 (6.50%) 0.84 (0.64, 1.10), 0.193 115 (9.03%) 86 (6.69%) 0.72 (0.54, 0.95), 0.020 0.453 
Cardiovascular death 0.83 (0.71, 0.96), 0.015 177 (11.86%) 161 (10.91%) 0.91 (0.73, 1.13), 0.382 182 (14.29%) 142 (11.04%) 0.75 (0.60, 0.93), 0.009 0.211 
All-cause mortality 0.88 (0.80, 0.96), 0.005 513 (34.36%) 477 (32.32%) 0.93 (0.82, 1.05), 0.247 460 (36.11%) 395 (30.72%) 0.82 (0.72, 0.94), 0.004 0.184 
 6 
 7 
Effect of therapy (vs. placebo) shown as hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) and p value. 5-year randomised trial: from randomisation to end of randomised trial (on-trial 8 
period). 20-year long-term follow-up: from randomisation to end of extended follow-up (on-trial plus post-trial periods). Results for the 15-year post-trial period only (from end of randomised trial to end of extended 9 
follow-up) did not materially differ from those in the 20-year long-term follow-up and are presented in eTable 5 in supplementary material. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. 10 
MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. See main text and supplementary material for endpoints 11 
definitions. To convert values for cholesterol to mmol/L, multiply by 0.02586.  12 
 13 
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TABLE 3. Risk of major adverse cardiovascular events in the subgroup of patients without diabetes and with a predicted 10-year ASCVD risk* below 1 
7.5% at baseline. 2 
 3 
Participants with  
predicted 10-year  
ASCVD risk <7.5%*  
and no diabetes 
LDL-C <190 mg/dL LDL-C ≥190 mg/dL 
Interaction p-
value between 
LDL-C grouping 
at baseline and 
randomised 
treatment 
Placebo 
(n=1085) 
Pravastatin 
(n=1064) 
HR (95% CI), p-value 
Placebo 
(n=856) 
Pravastatin 
(n=858) 
HR (95% CI), p-value 
5-year randomised trial period        
MACE 62 (5.7%) 48 (4.5%) 0.79 (0.54, 1.15), 0.21 64 (7.5%) 41 (4.8%) 0.62 (0.42, 0.92), 0.018 0.404 
20-year long-term follow-up        
MACE 230 (21.20%) 178 (16.73%) 0.76 (0.62, 0.92), 0.005 207 (24.18%) 161 (18.76%) 0.73 (0.60, 0.90), 0.003 0.832 
 4 
* ASCVD risk according to the Pooled Cohort Equations risk calculator (ref. 15). Effect of therapy (vs. placebo) shown as hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) and p value. 5-5 
year randomised trial: from randomisation to end of randomised trial (on-trial period). 20-year long-term follow-up: from randomisation to end of extended follow-up (on-trial plus post-trial periods). ASCVD: 6 
atherosclerotic cardiovascular disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and 7 
non-fatal stroke. To convert values for cholesterol to mmol/L, multiply by 0.02586. 8 
 9 
 10 
Principal Endpoints
Coronary Heart Disease
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
MACE
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Additional Endpoints explored
Coronary Heart Disease *
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
MACE plus coronary revascularisation
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
MACE * plus coronary revascularisation
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Coronary Heart Disease Death
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Coronary Heart Disease Death *
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Cardiovascular Death
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
All-cause Mortality
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Coronary Revascularisation
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Fatal or Non-fatal Stroke or TIA
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
p = 0.960
p = 0.958
p = 0.219
p = 0.805
p = 0.274
p = 0.838
p = 0.963
p = 0.992
p = 0.835
p = 0.416
p = 0.587
0.73 (0.59, 0.89), p = 0.002
0.72 (0.54, 0.97), p = 0.032
0.73 (0.55, 0.98), p = 0.033
0.75 (0.62, 0.91), p = 0.004
0.76 (0.58, 1.00), p = 0.048
0.75 (0.57, 0.98), p = 0.037
0.67 (0.54, 0.85), p < 0.001
0.58 (0.41, 0.81), p = 0.001
0.77 (0.57, 1.05), p = 0.103
0.76 (0.63, 0.91), p = 0.004
0.74 (0.57, 0.97), p = 0.028
0.78 (0.60, 1.00), p = 0.052
0.72 (0.59, 0.88), p < 0.001
0.64 (0.48, 0.85), p = 0.002
0.80 (0.61, 1.04), p = 0.095
0.91 (0.56, 1.48), p = 0.704
0.95 (0.49, 1.85), p = 0.887
0.86 (0.42. 1.76), p = 0.684
1.00 (0.60, 1.67), p = 0.994
1.01 (0.50, 2.02), p = 0.980
0.99 (0.46, 2.12), p = 0.969
0.84 (0.54, 1.30), p = 0.434
0.84 (0.46, 1.52), p = 0.568
0.84 (0.44, 1.60), p = 0.590
0.87 (0.64, 1.17), p = 0.356
0.89 (0.60, 1.33), p = 0.576
0.84 (0.53, 1.32), p = 0.446
0.72 (0.47, 1.10), p = 0.132
0.58 (0.30, 1.13), p = 0.108
0.84 (0.48, 1.46), p = 0.527
0.95 (0.66, 1.36), p = 0.773
1.04 (0.63, 1.72), p = 0.868
0.86 (0.51, 1.43), p = 0.555
-1 -0.5 0 0.5 1 1.5 2 2.5 3
Interaction
p-value HR (95% CI), p-value
0
1
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4
5
6
7
8
9
1
0
0 1 2 3 4 5
Years since randomisation
P
e
rc
e
n
ta
g
e
 w
it
h
 e
v
e
n
t
Placebo, LDL-C <1 90 mg/dL
Pravastatin, LDL-C <1 90 mg/dL
Placebo, LDL-C ≥1 90 mg/dL
Pravastatin, LDL-C ≥1 90 mg/dL
Coronary Heart Disease
Numbers at risk
Placebo, LDL-C <190:
Pravastatin, LDL-C <190:
Placebo, LDL-C ≥190:
Pravastatin, LDL-C ≥190:
564
591
478
489
1493
1476
1274
1286
1469
1457
1248
1267
1446
1440
1219
1253
1415
1415
1201
1231
1222
1242
1044
1088
HR (95%CI) Pravastatin vs. Placebo in those with LDL-C <190 mg/dL: 0.72 (0.54, 0.97), p=0.032
HR (95%CI) Pravastatin vs. Placebo in those with LDL-C ≥190 mg/dL: 0.73 (0.55, 0.98), p=0.033
Interaction p-value between cohorts: p=0.960
Major Adverse Cardiovascular Events
560
585
474
486
1493
1476
1274
1286
1468
1453
1246
1266
1444
1435
1217
1247
1413
1409
1194
1223
1216
1235
1036
1080
Numbers at risk
Placebo, LDL-C <190:
Pravastatin, LDL-C <190:
Placebo, LDL-C ≥190:
Pravastatin, LDL-C ≥190:
HR (95%CI) Pravastatin vs. Placebo in those with LDL-C <190 mg/dL: 0.76 (0.58, 1.00), p=0.048
HR (95%CI) Pravastatin vs. Placebo in those with LDL-C ≥190 mg/dL: 0.75 (0.57, 0.98), p=0.037
Interaction p-value between both cohorts: p=0.958
CHD death
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
Cardiovascular death
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
All-cause mortality
Overall primary prevention cohort
- LDL-C <190 mg/dL
- LDL-C ≥190 mg/dL
p = 0.453
p = 0.211
p = 0.184
0.78 (0.64, 0.94), p = 0.011
0.84 (0.64, 1.10), p = 0.193
0.72 (0.54, 0.95), p = 0.020
0.83 (0.71, 0.96), p = 0.015
0.91 (0.73, 1.13), p = 0.382
0.75 (0.60, 0.93), p = 0.009
0.88 (0.80, 0.96), p = 0.005
0.93 (0.82, 1.05), p = 0.247
0.82 (0.72, 0.94), p = 0.004
-0.5 -0.25 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
Interaction
p-value HR (95% CI), p-value
p = 0.086
p = 0.106
p = 0.046
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
-1 -0.5 0 0.5 1 1.5 2 2.5
Coronary Heart Disease MACE plus coronary revascularisation
p = 0.030
p = 0.047
p = 0.015
Absolute reduction in LDL-C levels
Placebo
Absolute fall <39 mg/dL
Absolute fall ≥39 mg/dL
Relative reduction in LDL-C levels
Placebo
Percentage reduction <30%
Percentage reduction ≥30%
On-treatment LDL-C levels
Placebo
On-treatment ≥174 mg/dL
On-treatment 145 to <174 mg/dL
On-treatment <145 mg/dL
-1.5 -1 -0.5 0 0.5 1 1.5 2 2.5
Interaction
p-value
Interaction
p-valueHR (95% CI), p-value
Ref. group
0.89 (0.57, 1.40), p = 0.612
0.61 (0.42, 0.88), p = 0.008
Ref. group
0.76 (0.53, 1.10), p = 0.148
0.58 (0.37, 0.92), p = 0.021
Ref. group
1.09 (0.69, 1.71), p = 0.724
0.58 (0.35, 0.95), p = 0.030
0.56 (0.35, 0.89), p = 0.014 
HR (95% CI), p-value
Ref. group
0.88 (0.58, 1.32), p = 0.524
0.70 (0.51, 0.96), p = 0.027
Ref. group
0.80 (0.57, 1.10), p = 0.171
0.68 (0.46, 1.01), p = 0.054
Ref. group
1.06 (0.70, 1.60), p = 0.772
0.67 (0.44, 1.02), p = 0.064
0.64 (0.43, 0.95), p = 0.027 
